Cisatracurium Besylate Injection USP Multidose Recall
Areazine synthesizes this Health Canada recall directly from Health Canada's official public data feed. See our methodology for full source attribution and refresh cadence.
Health Canada recalls specific lots of Cisatracurium Besylate Injection USP Multidose due to potential out-of-specification levels of the degradation product Benzaldehyde.
What this Health Canada recall tells you, and what most readers miss
This notice was issued by Health Canada on August 19, 2026 and geographically references Canada. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Product & Food Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, health-canada, pharmaceutical.
What Happened
The level of the degradation product Benzaldehyde may be out of specification in the affected lots of Cisatracurium Besylate Injection USP Multidose.
Which Products Are Affected
- Brand: Omega Laboratories Limited
- Product Name: Cisatracurium Besylate Injection USP Multidose
- DIN: 02408813
- Dosage Form: Solution
- Strength: Cisatracurium (Cisatracurium besilate) 2 mg/mL
- Lot Numbers: B5C646A, B5D664A
Depth of recall: Retailers. Company: Juno Pharma Canada Inc. (Omega Laboratories Limited), 11177 Rue Hamon, Montreal, QC, Canada H3M 3E4.
What You Should Do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Why This Matters
This recall addresses a potential quality issue with a prescription injectable medication distributed in Canada.
Source
Original source: Health Canada Official Notice ↗
Related Product & Food Recalls
All Product & Food Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this Health Canada recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,267 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to August 19, 2026.
Frequently Asked Questions
Common questions about this Health Canada recall.